Geode Capital Management
ACRS icon

Geode Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Geode Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.9M Buy
3,190,058
+766,367
+32% +$3.42M ﹤0.01% 2251
2026
Q1 		$9.09M Buy
2,423,691
+30,919
+1% +$104K ﹤0.01% 2438
2025
Q4 		$7.2M Buy
2,392,772
+3,241
+0.1% +$8.19K ﹤0.01% 2568
2025
Q3 		$4.54M Sell
2,389,531
-75,248
-3% -$131K ﹤0.01% 2833
2025
Q2 		$3.5M Buy
2,464,779
+1,282,042
+108% +$1.73M ﹤0.01% 2910
2025
Q1 		$1.81M Buy
1,182,737
+393,140
+50% +$839K ﹤0.01% 3076
2024
Q4 		$1.96M Sell
789,597
-56,849
-7% -$141K ﹤0.01% 3134
2024
Q3 		$974K Buy
846,446
+72,309
+9% +$88.7K ﹤0.01% 3363
2024
Q2 		$852K Sell
774,137
-790,917
-51% -$929K ﹤0.01% 3372
2024
Q1 		$1.94M Buy
1,565,054
+171,506
+12% +$205K ﹤0.01% 3122
2023
Q4 		$1.46M Buy
1,393,548
+56,466
+4% +$172K ﹤0.01% 3204
2023
Q3 		$9.16M Buy
1,337,082
+99,673
+8% +$852K ﹤0.01% 2322
2023
Q2 		$12.8M Buy
1,237,409
+122,837
+11% +$1.11M ﹤0.01% 2140
2023
Q1 		$9.02M Buy
1,114,572
+55,824
+5% +$708K ﹤0.01% 2316
2022
Q4 		$16.7M Buy
1,058,748
+30,025
+3% +$483K ﹤0.01% 1897
2022
Q3 		$16.2M Buy
1,028,723
+71,507
+7% +$1.13M ﹤0.01% 1895
2022
Q2 		$13.4M Buy
957,216
+110,825
+13% +$1.55M ﹤0.01% 2044
2022
Q1 		$14.6M Buy
846,391
+37,929
+5% +$517K ﹤0.01% 2097
2021
Q4 		$11.8M Buy
808,462
+12,636
+2% +$191K ﹤0.01% 2340
2021
Q3 		$14.3M Buy
795,826
+77,069
+11% +$1.24M ﹤0.01% 2192
2021
Q2 		$12.6M Buy
718,757
+341,893
+91% +$7.77M ﹤0.01% 2295
2021
Q1 		$9.5M Buy
376,864
+51,888
+16% +$1.01M ﹤0.01% 2398
2020
Q4 		$2.1M Sell
324,976
-77,096
-19% -$325K ﹤0.01% 3055
2020
Q3 		$1.03M Sell
402,072
-10,503
-3% -$23.5K ﹤0.01% 3198
2020
Q2 		$668K Sell
412,575
-174,519
-30% -$234K ﹤0.01% 3273
2020
Q1 		$610K Buy
587,094
+5,911
+1% +$8.05K ﹤0.01% 3213
2019
Q4 		$1.1M Buy
581,183
+90,067
+18% +$149K ﹤0.01% 3249
2019
Q3 		$530K Buy
491,116
+5,031
+1% +$7.14K ﹤0.01% 3454
2019
Q2 		$1.06M Buy
486,085
+18,992
+4% +$104K ﹤0.01% 3223
2019
Q1 		$2.8M Buy
467,093
+87,086
+23% +$577K ﹤0.01% 2647
2018
Q4 		$2.81M Buy
380,007
+105,361
+38% +$1.09M ﹤0.01% 2568
2018
Q3 		$3.99M Buy
274,646
+7,993
+3% +$137K ﹤0.01% 2502
2018
Q2 		$5.33M Buy
266,653
+21,783
+9% +$402K ﹤0.01% 2286
2018
Q1 		$4.29M Buy
244,870
+19,197
+9% +$407K ﹤0.01% 2333
2017
Q4 		$5.57M Buy
225,673
+13,664
+6% +$333K ﹤0.01% 2150
2017
Q3 		$5.47M Buy
212,009
+68,312
+48% +$1.83M ﹤0.01% 2146
2017
Q2 		$3.9M Buy
143,697
+25,661
+22% +$698K ﹤0.01% 2314
2017
Q1 		$3.52M Buy
118,036
+14,126
+14% +$407K ﹤0.01% 2324
2016
Q4 		$2.82M Buy
103,910
+52,765
+103% +$1.35M ﹤0.01% 2429
2016
Q3 		$1.31M Buy
51,145
+2,120
+4% +$45K ﹤0.01% 2802
2016
Q2 		$905K Buy
49,025
+5,779
+13% +$115K ﹤0.01% 2951
2016
Q1 		$819 Buy
43,246
+6,679
+18% +$128K ﹤0.01% 2990
2015
Q4 		$985K Buy
+36,567
New +$712K ﹤0.01% 2922

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Geode Capital Management's ACRS Position: Q2 2026 in Review

Geode Capital Management increased its Aclaris Therapeutics (ACRS) stake by 32% in Q2 2026, buying an estimated $3.42M and bringing the position to 3,190,058 shares worth $16.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2251.

Geode Capital Management first reported a position in ACRS in Q4 2015 and has held it in 43 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Geode Capital Management held 3,190,058 shares of Aclaris Therapeutics worth $16.9M as of Q2 2026.
  • Geode Capital Management bought 766,367 Aclaris Therapeutics shares in Q2 2026, an estimated $3.42M.
  • Aclaris Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2251 holding.
  • Geode Capital Management first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 43 quarters since.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.